Read by QxMD icon Read

Journal of Ocular Pharmacology and Therapeutics

David Callanan, Derek Kunimoto, Raj K Maturi, Sunil S Patel, Giovanni Staurenghi, Sebastian Wolf, Janet K Cheetham, Thomas C Hohman, Kimmie Kim, Francisco J López, Susan Schneider
PURPOSE: To evaluate safety and efficacy of the vascular endothelial growth factor binding protein abicipar pegol (abicipar) versus ranibizumab for neovascular age-related macular degeneration. METHODS: Phase 2, multicenter, randomized, double-masked comparison (REACH study, stage 3). Patients (n = 64) received intravitreal injections of abicipar 1 mg or 2 mg at baseline, week 4, and week 8 (3 injections) or ranibizumab 0.5 mg at baseline and monthly (5 injections)...
November 9, 2018: Journal of Ocular Pharmacology and Therapeutics
Sandamali A Ekanayaka, Sharon A McClellan, Xudong Peng, Ronald P Barrett, Rebecca Francis, Linda D Hazlett
PURPOSE: High mobility group box 1 (HMGB1) contributes to adverse disease outcome in Pseudomonas aeruginosa keratitis. This study tests Box A, an HMGB1 antagonist, in a model of the disease. METHODS: C57BL/6 mice (B6) were injected subconjunctivally (1 day before infection) with Box A or phosphate-buffered saline (PBS), infected with P. aeruginosa strain ATCC 19660, and injected intraperitoneally with Box A or PBS at 1 and 3 days postinfection (p.i.). Clinical scores, photographs with a slit lamp camera, real-time polymerase chain reaction (RT-PCR), western blot, immunohistochemistry, enzyme-linked immunosorbent assay (ELISA), myeloperoxidase (MPO), and bacterial plate count were used to assess disease outcome...
November 8, 2018: Journal of Ocular Pharmacology and Therapeutics
Isabeau Houben, Julie De Zaeytijd, Catherine Deghislage, N Andrew Frost, Ivo Nijs, Joachim Van Calster
PURPOSE: To evaluate the efficacy of dexamethasone intravitreal implants (DEX implant) in patients with treatment-resistant macular edema (ME) owing to branch and central retinal vein occlusion (BRVO/CRVO), and the influence of prior vitrectomy on this treatment. METHODS: Multicenter retrospective chart review was performed on 40 CRVO and 32 BRVO eyes with persistent ME despite intravitreal anti-vascular endothelial growth factor agents and/or intravitreal triamcinolone, and/or laser therapy...
November 7, 2018: Journal of Ocular Pharmacology and Therapeutics
Katrin Voelter, Christoph Tappeiner, Karina Klein, Nicole Borel, Deborah Bruetsch, Fernando Laguna Sanz, Simon Anton Pot
PURPOSE: Desmoteplase (DSPA) was evaluated and compared with tissue plasminogen activator (t-PA) for its intraocular fibrinolytic effect and short-term toxicity in an in vivo study using rabbit eyes. METHODS: Fibrin clots were induced in the anterior chamber of 44 rabbit eyes, and drug efficacy was measured by clot size reduction over 24 h. Topical DSPA eye drops (1.4 and 2 mg/mL) were compared with vehicle solution in a multiple-drop regimen in 8 animals per group...
October 30, 2018: Journal of Ocular Pharmacology and Therapeutics
Gary D Novack
No abstract text is available yet for this article.
October 30, 2018: Journal of Ocular Pharmacology and Therapeutics
Gary D Novack
No abstract text is available yet for this article.
October 26, 2018: Journal of Ocular Pharmacology and Therapeutics
Hande Celiker, Haluk Kazokoglu, Haner Direskeneli
PURPOSE: To investigate factors affecting relapse and remission in patients with Behçet uveitis (BU) in the context of using the interferon alpha2a (IFNα2a) therapy. METHODS: Clinical records were reviewed of 32 patients (totaling 54 eyes) presenting with severe BU who had been treated with IFNα2a therapy. Factors influencing relapsing-remitting course of BU during IFNα2a therapy and after the cessation of the agent were evaluated. Possible affecting factors of recurrence were age, gender, duration of the Behçet disease, time elapsed before starting the drug, number of relapses before the starting of IFNα2a, laterality, and presence of panuveitis...
October 25, 2018: Journal of Ocular Pharmacology and Therapeutics
Yoon Sun Ree, Hyun-Moon Back, Hwi-Yeol Yun, Ji Hyun Ahn, Eun Sun Son, Jung Woo Han, Chuhl Joo Lyu, Sandy Jeong Rhie
PURPOSE: Retinoblastoma is a childhood malignancy of the retina. To increase the exposures of systemic chemotherapy, high-dose cyclosporine, as a P-glycoprotein modulating agent, has been combined with a standard chemotherapy. However, the effective and safe dose of cyclosporine has not been well evaluated. This study is to optimize cyclosporine dose using population pharmacokinetic modeling. METHODS: Clinical data were obtained from 161 systemic chemotherapy cycles of 34 pediatric retinoblastoma patients between December 2006 and April 2015...
October 18, 2018: Journal of Ocular Pharmacology and Therapeutics
Jennifer R Seal, Michael R Robinson, James Burke, Marina Bejanian, Michael Coote, Mayssa Attar
PURPOSE: To explore the ocular distribution of bimatoprost after intracameral administration of a biodegradable sustained-release bimatoprost implant (Bimatoprost SR) versus repeated topical administration of bimatoprost 0.03% ophthalmic solution in dogs. Bimatoprost SR and topical bimatoprost 0.03% previously were shown to have similar intraocular pressure-lowering effects in humans in a phase 1/2 clinical trial. METHODS: Twenty-four beagle dogs received either once-daily topical bimatoprost 0...
October 18, 2018: Journal of Ocular Pharmacology and Therapeutics
Stephan Szegedi, Ulrike Scheschy, Doreen Schmidl, Valentin Aranha Dos Santos, Hannes Stegmann, Narine Adzhemian, Klemens Fondi, Ahmed M Bata, René M Werkmeister, Chantal Couderc, Leopold Schmetterer, Gerhard Garhofer
PURPOSE: This study investigated the effect of single administration of 2 different hyaluronic acid-based topical lubricants on tear film thickness (TFT) in patients with moderate-to-severe dry eye disease (DED). METHODS: Sixty patients were randomized to receive eye drops containing unpreserved sodium hyaluronate, triglycerides, and phospholipids (HTP), unpreserved sodium hyaluronate (HA), or unpreserved sodium chloride (NaCl). TFT and lipid layer thickness (LLT) were assessed before and at defined time points after single instillation with a custom-built ultrahigh-resolution optical coherence tomography system and a white light interferometer...
October 16, 2018: Journal of Ocular Pharmacology and Therapeutics
Annalisa La Gatta, Luisana Corsuto, Rosanna Salzillo, Antonella D'Agostino, Mario De Rosa, Adele Bracco, Chiara Schiraldi
PURPOSE: The purpose of this in vitro study was to assess the potential benefits of eye drops based on hybrid cooperative complexes (HCCs) obtained from high and low molecular weight hyaluronic acid (HA). METHODS: Rheological measurements were performed to adjust the HCC concentration toward optimal resistance to drainage from the ocular surface. The viscosity and mucoadhesion profiles of the optimized preparation were derived. Primary porcine corneal epithelial cells were used for biological studies...
October 16, 2018: Journal of Ocular Pharmacology and Therapeutics
Inhee Moon, Hyun Goo Kang, Areum Yeo, Hyemi Noh, Hyeon Chang Kim, Jong Suk Song, Yong Woo Ji, Hyung Keun Lee
PURPOSE: To determine the mucinogenic effect of dry eye (DE) treatment drugs currently in use, we compared the levels of mucin production and inflammatory cytokine expression on the ocular surfaces using a DE-induced mice model. METHODS: C57BL/6 mice were separated into 6 groups: a control group, DE-induced mice with the vehicle and treated with cyclosporine A (CsA), rebamipide (Reb), diquafosol tetrasodium (DQS), or prednisolone (Pred). The mRNA expression of MUC 1, 4, 16, 5AC, and proinflammatory cytokines on the corneal epithelia were determined by quantitative real-time polymerase chain reaction...
October 16, 2018: Journal of Ocular Pharmacology and Therapeutics
Andrew S Goldstein, Benjamin T Aldrich, Jessica M Skeie, Gregory A Schmidt, Cynthia R Reed, M Bridget Zimmerman, Mark A Greiner
PURPOSE: To determine how the Rho kinase inhibitor, ripasudil, affects metabolic function and cell viability in donor human corneal endothelial cells (HCECs). METHODS: Endothelial cell-Descemet membrane (EDM) tissues were treated with 10 μM ripasudil and assayed for mitochondrial and glycolytic activity using extracellular flux analysis and then compared to untreated controls. In addition, EDM tissues with a 24-h ripasudil treatment and control tissues were exposed to 1 μM staurosporine to induce apoptosis and then analyzed for cell viability using apoptosis and necrosis assays...
October 12, 2018: Journal of Ocular Pharmacology and Therapeutics
Mehmet Orkun Sevik, Semra Akkaya Turhan, Ebru Toker
PURPOSE: The aim of the study was to assess the efficacy of a topical regenerating agent (RGTA) for management of persistent epithelial defects (PEDs) resistant to conventional therapy. METHODS: Twenty-one patients (23 eyes) with PEDs despite the use of conventional therapy for lagophthalmos (n = 4), neurotrophic ulcer (n = 9), chemical burn (n = 3), Stevens-Johnson syndrome (n = 1), atopic keratoconjunctivitis (n = 1), severe dry eye (n = 2), peripheral ulcerative keratitis (n = 1), fungal keratitis (n = 1), and bacterial keratitis (n = 1) were enrolled in the study...
October 12, 2018: Journal of Ocular Pharmacology and Therapeutics
Philippe Daull, Elisabeth Raymond, Laurence Feraille, Jean-Sébastien Garrigue
PURPOSE: Preservative-free cationic emulsion-based artificial tear (AT) is an innovative eye drop based on the Novasorb® technology with cetalkonium chloride (CKC) as the cationic agent. The cationic emulsion Cationorm is designed for the management of mild-to-moderate dry eye disease (DED) patients that present cornea epithelium alterations. The aim of the present study was to evaluate the safety and tolerability of overdosed ATs by altered corneal epithelium in vivo and assess the usefulness of the ex vivo eye irritation test (EVEIT) as a predictive alternate toxicity test method...
October 12, 2018: Journal of Ocular Pharmacology and Therapeutics
Yoon Hong Chun, Jin Uk Beak, Hyun-Seung Kim, Kyung-Sun Na
PURPOSE: Dry eye disease (DED) of ocular graft-versus-host disease (GVHD) is a common complication after allogeneic hematopoietic stem cell transplantation (HSCT). Ongoing inflammation and irreversible fibrotic changes of the ocular surface and adnexa are obstacles for effective treatment of ocular GVHD. We hypothesized that topical cyclosporine A (CsA) pretreatment might be effective in preventing ocular GVHD. METHODS: In this prospective, randomized, comparative study, patients were randomly assigned to the topical CsA treatment (4 times daily in both eyes for a month before allogeneic HSCT and continued use of eye drops after transplantation) or control (no treatment) groups...
October 5, 2018: Journal of Ocular Pharmacology and Therapeutics
Bin-Wu Lin, Wei-Lan Huang, Lu Wang, Zi-Man Chen
PURPOSE: To compare the effects of FK-506, cyclosporin A (CsA), and sodium hyaluronate (HA) eye drops for the treatment of botulinum toxin B (BTX-B)-induced mouse dry eye. METHODS: CBA/J mice were randomized into 5 groups. The groups received treatment with eye drops containing 0.025% FK-506 combined with 0.3% HA (FK-506+HA group), 0.025% FK-506 (FK-506 group), 0.05% CsA (CsA group), 0.3% HA (HA group), or 0.9% saline (saline group) 3 days after an intralacrimal gland injection with 20 mU of BTX-B...
September 18, 2018: Journal of Ocular Pharmacology and Therapeutics
Chang Ho Yoon, Jong Woo Park, Jin Suk Ryu, Mee Kum Kim, Joo Youn Oh
PURPOSE: To investigate the effect of tacrolimus ointment on corneal epithelium. METHODS: Eight-week-old male BALB/c mice were divided into 3 groups. In group 1, no injury was made. In group 2, the central 2-mm corneal epithelium was scraped off. In group 3, the whole corneal and limbal epithelium was removed after absolute ethanol application. In each group, the corneas were observed and treated daily with 0.03% or 0.1% tacrolimus ointment (Protopic® ). The viability of cultivated human corneal epithelial cells was also examined after 24-h incubation with various concentrations of tacrolimus...
September 15, 2018: Journal of Ocular Pharmacology and Therapeutics
Marija Bozic, Milenko Stojkovic, Miroslav Knezevic, Ivan Marjanovic, Anica Bobic-Radovanovic
PURPOSE: To test the hypothesis that the use of refrigerated fixed combination of dorzolamide 2% plus timolol 0.5% solution (COSOPT® ) is associated with less ocular discomfort compared with the use of this solution kept at room temperature. METHODS: In this prospective comparative study, 30 primary open-angle patients and 30 healthy subjects filled in the questionnaire on symptoms (Ocular Surface Disease Index) and subjective stinging feeling scale (1-10), at the start of study and 30 days after continuous use of refrigerated fixed combination or placebo eye drops...
September 11, 2018: Journal of Ocular Pharmacology and Therapeutics
Diana Stanton, Christopher Batich, Gregory Schultz, Daniel Gibson, Carla Guidi, Qingping Yang, Alexandra Bechtle, Richard Eiferman
PURPOSE: Multiuse eye drops must maintain sterility and typically accomplish this by added preservatives. However, preservatives often cause harmful side effects. A gauze barrier dressing ("BIOGUARD® ") recently cleared by the FDA has an immobilized poly diallyldimethylammonium chloride (p-DADMAC) coating and is an effective antimicrobial with minimal compound release into solution. To implement use of this dressing as a replacement for preservatives in multidose eye drop bottles, its ability to maintain sterility without interacting with the active ingredient (AI) of the ophthalmic medication was tested...
October 2018: Journal of Ocular Pharmacology and Therapeutics
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"